Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Schizophrenia bulletin

• Publication date

  2016-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1093/schbul/sbv151PMID 26683625PMCID PMC4838083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glutamate and dopamine in schizophrenia: An update for the 21st century

  2015cited by this paper
• The Maudsley Prescribing Guidelines in Psychiatry

  2015cited by this paper
• Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.

  2014cited by this paper
• Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users

  2014cited by this paper
• Synaptic Proteins in the Postmortem Anterior Cingulate Cortex in Schizophrenia: Relationship to Treatment and Treatment Response

  2014cited by this paper
• A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic).

  2014cited by this paper
• Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

  2014cited by this paper
• Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

  2014cited by this paper
• Clozapine Prescribing in a Canadian Outpatient Population

  2013cited by this paper
• Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia

  2013cited by this paper
• Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.

  2013cited by this paper
• Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study.

  2013cited by this paper
• Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis

  2013cited by this paper
• Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation

  2012cited by this paper
• Tetrabenazine Augmentation in Treatment-Resistant Schizophrenia: A 12-Week, Double-Blind, Placebo-Controlled Trial

  2012cited by this paper
• The nature of dopamine dysfunction in schizophrenia and what this means for treatment.

  2012cited by this paper
• Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.

  2012cited by this paper
• Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia

  2012cited by this paper
• Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.

  2012cited by this paper
• Addressing nonresponse in schizophrenia.

  2012cited by this paper
• Clozapine, but not haloperidol, enhances glial d‐serine and L‐glutamate release in rat frontal cortex and primary cultured astrocytes

  2012cited by this paper
• Different serine and glycine metabolism in patients with schizophrenia receiving clozapine.

  2012cited by this paper
• Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia

  2012cited by this paper
• Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla.

  2011cited by this paper
• Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia

  2011cited by this paper
• Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis

  2011cited by this paper
• Dopamine D2 Receptor Occupancy and Clinical Effects: A Systematic Review and Pooled Analysis

  2011cited by this paper
• Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7T.

  2010cited by this paper
• International consensus study of antipsychotic dosing.

  2010cited by this paper
• Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.

  2010cited by this paper
• 1H-MRS at 4 Tesla in minimally treated early schizophrenia

  2010cited by this paper
• Patterns of clozapine prescribing in a mental health service in New Zealand

  2010cited by this paper
• Effects of risperidone on glutamate receptor subtypes in developing rat brain.

  2009cited by this paper
• Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume.

  2009cited by this paper
• Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

  2009cited by this paper
• Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.

  2008cited by this paper
• Effects of risperidone on dopamine receptor subtypes in developing rat brain.

  2007cited by this paper
• Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia

  2007cited by this paper
• Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.

  2007cited by this paper
• Clozapine underutilization and discontinuation in African Americans due to leucopenia.

  2007cited by this paper
• NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons

  2007cited by this paper
• Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.

  2007cited by this paper
• Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.

  2005cited by this paper
• Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function

  2005cited by this paper
• Remission in schizophrenia: proposed criteria and rationale for consensus.

  2005cited by this paper
• Practice guideline for the treatment of patients with schizophrenia, second edition.

  2004cited by this paper
• Clozapine but not Haloperidol Re-establishes Normal Task-Activated rCBF Patterns in Schizophrenia within the Anterior Cingulate Cortex

  2004cited by this paper
• Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

  2004cited by this paper
• Treatment Refractory Schizophrenia

  2004cited by this paper
• Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex

  2004cited by this paper
• Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES

  2004cited by this paper
• AIC model selection using Akaike weights

  2004cited by this paper
• Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS.

  2003cited by this paper
• Long-Term Effects of Olanzapine, Risperidone, and Quetiapine on Ionotropic Glutamate Receptor Types: Implications for Antipsychotic Drug Treatment

  2003cited by this paper
• Functional effects of antipsychotic drugs: comparing clozapine with haloperidol.

  2003cited by this paper
• Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review.

  2003cited by this paper
• Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers.

  2002cited by this paper
• Management of treatment resistance in schizophrenia.

  2001cited by this paper
• Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.

  2001cited by this paper
• Automatic quantitation of localized in vivo 1H spectra with LCModel

  2001cited by this paper
• Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

  2000cited by this paper
• Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

  2000cited by this paper
• NMDA receptor hypofunction model of schizophrenia.

  1999cited by this paper
• Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.

  1998cited by this paper
• Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.

  1997cited by this paper
• Practice guideline for the treatment of patients with schizophrenia

  1997cited by this paper
• Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study

  1993cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987influential reference

• Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials

  2026cites this paper
• [Biological aspects of drug resistance in schizophrenia].

  2026cites this paper
• Neuropharmacological targets for schizophrenia treatment: An update.

  2025cites this paper
• The relationship between serum Interleukin- 6, Interleukin- 18, Interleukin- 2, Eotaxin-1, Monocyte Chemoattractant Protein 1 levels and cognitive functions in treatment-resistant schizophrenia.

  2025cites this paper
• Advancing Understanding of Treatment Response in Schizophrenia With Psychosis Using a Novel Dynamic Reward Task.

  2025cites this paper
• Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis

  2025cites this paper
• Changes in glutamate levels in anterior cingulate cortex following 16 weeks of antipsychotic treatment in antipsychotic-naïve first-episode psychosis patients

  2025cites this paper
• GABA, glutamate dynamics and BOLD observed during cognitive processing in psychosis patients with hallucinatory traits

  2025cites this paper
• Longitudinal changes in striatocortical connectivity in first-episode psychosis associated with the emergence of treatment resistance

  2025cites this paper
• REMARKABLE EFFICACY OF EVENAMIDE, A GLUTAMATE ANTAGONIST, AS AN ADD-ON TO ANTIPSYCHOTICS IN PATIENTS WITH TREATMENT RESISTANT SCHIZOPHRENIA (TRS): RESULTS FROM A ONE-YEAR, OPEN- LABEL, DOSE-COMPARATIVE, RANDOMIZED, TREATMENT TRIAL

  2025cites this paper
• Machine learning-based prediction of antipsychotic efficacy from brain gray matter structure in drug-naive first-episode schizophrenia

  2025cites this paper
• EVENAMIDE AS ADD-ON TREATMENT FOR PATIENTS WITH CHRONIC SCHIZOPHRENIA NOT RESPONDING ADEQUATELY TO THEIR CURRENT ANTIPSYCHOTIC MEDICATION: RESULTS OF A POTENTIALLY PIVOTAL, PHASE II/III, INTERNATIONAL, RANDOMIZED, DOUBLE BLIND, PLACEBO- CONTROLLED TRIAL

  2025cites this paper
• Molecular and topographic mapping of antipsychotic effects: a meta-analysis of postsynaptic density proteins in animal models with translational implications

  2025cites this paper
• Glutamate-Based Therapeutic Strategies for Schizophrenia: Emerging Approaches Beyond Dopamine

  2025cites this paper
• Association of astrocyte-specific gene expression in the dorsolateral prefrontal cortex with clozapine treatment in schizophrenia

  2025cites this paper
• Differentially expressed mRNAs of neural signaling pathway genes in peripheral blood leukocytes as biomarkers for schizophrenia

  2025cites this paper
• Functional connectivity of the striatum in psychosis: meta-analysis of functional Magnetic Resonance Imaging studies and replication on an independent sample.

  2025cites this paper
• Metabolic Syndrome and Schizophrenia: Adding a Piece to the Interplay Between the Kynurenine Pathway and Inflammation

  2025cites this paper
• Deep transcranial magnetic stimulation over the anterior cingulate cortex in treatment-resistant schizophrenia: A pilot double-blind, randomized controlled trial.

  2025cites this paper
• Clinical Deep Phenotyping of Treatment Response in Schizophrenia (CDP-STAR): design and methodology of a prospective multimodal observational study

  2025cites this paper
• The hypothesis of biologically based subtypes of schizophrenia: a 10‐year update

  2025cites this paper
• Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study.

  2025cites this paper
• Subtyping schizophrenia via machine learning by using structural neuroimaging

  2025cites this paper
• Molecular Underpinning of Treatment-Resistant Schizophrenia: A Putative Different Neurobiology from Treatment-Responsive Schizophrenia

  2025cites this paper
• Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial

  2024cites this paper
• Psychedelics and schizophrenia: a double-edged sword

  2024cites this paper
• Glutamate, GABA and NAA in treatment-resistant schizophrenia: a systematic review of the effect of clozapine and group differences between clozapine-responders and non-responders.

  2024cites this paper
• Functional Connectivity Biomarkers in Schizophrenia.

  2024cites this paper
• Glutamate and GABA levels in the anterior cingulate cortex in treatment resistant first episode psychosis patients.

  2024influential citation
• NMDA glutamate receptor antagonist MK‐801 induces proteome changes in adult human brain slices which are partially counteracted by haloperidol and clozapine

  2024cites this paper
• Gene expression imputation provides clinical and biological insights into treatment-resistant schizophrenia polygenic risk.

  2024cites this paper
• Distinct alterations in probabilistic reversal learning across at-risk mental state, first episode psychosis and persistent schizophrenia

  2024cites this paper
• Addressing brain metabolic connectivity in treatment-resistant schizophrenia: a novel graph theory-driven application of 18F-FDG-PET with antipsychotic dose correction

  2024cites this paper
• Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study

  2024cites this paper
• Response to clozapine in treatment resistant schizophrenia is related to alterations in regional cerebral blood flow

  2024cites this paper
• In Vivo Reactive Astrocyte Imaging in Patients With Schizophrenia Using Fluorine 18–Labeled THK5351

  2024cites this paper
• Clozapine treatment and astrocyte activity in treatment resistant schizophrenia: A proton magnetic resonance spectroscopy study.

  2024cites this paper
• CLEAR – clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings

  2024cites this paper
• Association of SLC6A3 variants with treatment-resistant schizophrenia: a genetic association study of dopamine-related genes in schizophrenia

  2024cites this paper
• Resting state and activated brain glutamate–glutamine, brain lactate, cognition, and psychopathology among males with schizophrenia: A 3 Tesla proton magnetic resonance spectroscopic (1H-MRS) study

  2024cites this paper
• New drug treatments for schizophrenia: a review of approaches to target circuit dysfunction.

  2024cites this paper
• Deterioration in cognitive control related mPFC function underlying development of treatment resistance in early psychosis

  2024cites this paper
• Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice.

  2024cites this paper
• Exploring causal mechanisms of psychosis risk

  2024cites this paper
• The mechanisms of persisting disability in schizophrenia: imprecise predictive coding via cortico-striatal-thalamo-cortical loop dysfunction.

  2024cites this paper
• Electrophysiological Markers Predicting Antipsychotic Treatment Response in Patients with Schizophrenia: A Retrospective Study

  2024cites this paper
• Psychotic disorders as a framework for precision psychiatry

  2023cites this paper
• Greater Choline-Containing Compounds and Myo-inositol in Treatment-Resistant vs. Responsive Schizophrenia: A 1H-Magnetic Resonance Spectroscopy Meta-Analysis.

  2023cites this paper
• A systematic review of neuroimaging studies of clozapine-resistant schizophrenia

  2023cites this paper
• Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex

  2023cites this paper
• Mismatch negativity in schizophrenia spectrum and bipolar disorders: Group and sex differences and associations with symptom severity.

  2023cites this paper
• The brain on the beat: How music may heal schizophrenia.

  2023cites this paper
• Genetic variation in glutamatergic genes moderates the effects of childhood adversity on brain volume and IQ in treatment-resistant schizophrenia

  2023cites this paper
• Estimating multimodal brain variability in schizophrenia spectrum disorders: A worldwide ENIGMA study

  2023cites this paper
• Neuroimaging glutamatergic mechanisms differentiating antipsychotic treatment-response

  2023cites this paper
• Epigenetic regulation of metabotropic glutamate 2/3 receptors: Potential role for ultra-resistant schizophrenia?

  2023cites this paper
• The association between peripheral inflammation, brain glutamate and antipsychotic response in Schizophrenia: Data from the STRATA collaboration

  2023cites this paper
• Prefrontal cortex-specific Dcc deletion induces schizophrenia-related behavioral phenotypes and fail to be rescued by olanzapine treatment.

  2023cites this paper
• Candidate biomarkers in psychiatric disorders: state of the field

  2023cites this paper
• Disease-specific resting-state EEG network variations in schizophrenia revealed by the contrastive machine learning.

  2023cites this paper
• The kynurenine pathway in treatment-resistant schizophrenia at the crossroads between pathophysiology and pharmacotherapy.

  2023cites this paper
• The phenomenon of therapeutic resistance in the treatment of schizophrenia: the possibilities of modern diagnostics and methods of anti-resistant effects

  2023cites this paper
• Resting-state functional MRI in treatment-resistant schizophrenia

  2023cites this paper
• Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment

  2023cites this paper
• Schizophrenia Synaptic Pathology and Antipsychotic Treatment in the Framework of Oxidative and Mitochondrial Dysfunction: Translational Highlights for the Clinics and Treatment

  2023cites this paper
• The drug treatment deadlock in psychiatry and the route forward

  2023cites this paper
• Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis

  2023cites this paper
• Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal

  2023cites this paper
• Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia

  2023cites this paper
• Cortical morphological heterogeneity of schizophrenia and its relationship with glutamatergic receptor variations

  2023cites this paper
• Treatment-resistant schizophrenia: How far have we traveled?

  2022cites this paper
• Altered Patterns of Brain Glucose Metabolism Involve More Extensive and Discrete Cortical Areas in Treatment-resistant Schizophrenia Patients Compared to Responder Patients and Controls: Results From a Head-to-Head 2-[18F]-FDG-PET Study.

  2022cites this paper
• Postmortem Brains: What Can Proteomics Tell us About the Sources of Schizophrenia?

  2022cites this paper
• The effect of antipsychotics on glutamate levels in the anterior cingulate cortex and clinical response: A 1H-MRS study in first-episode psychosis patients

  2022cites this paper
• A longitudinal investigation of GABA, glutamate, and glutamine across the insula during antipsychotic treatment of first-episode schizophrenia.

  2022cites this paper
• Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia

  2022cites this paper
• Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics

  2022cites this paper
• A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia

  2022cites this paper
• Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study

  2022cites this paper
• Antipsychotics-Induced Changes in Synaptic Architecture and Functional Connectivity: Translational Implications for Treatment Response and Resistance

  2022cites this paper
• Recognition of the Multi-class Schizophrenia Based on the Resting-State EEG Network Topology

  2022cites this paper
• Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels

  2022cites this paper
• Altered glutamate level and its association with working memory among patients with treatment-resistant schizophrenia (TRS): a proton magnetic resonance spectroscopy study

  2022cites this paper
• Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia

  2022cites this paper
• Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics

  2022influential citation
• Neurofunctional correlates of glutamate and GABA imbalance in psychosis: A systematic review.

  2022cites this paper
• Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration

  2022cites this paper
• Altered Neuroanatomical Signatures of Patients With Treatment-Resistant Schizophrenia Compared to Patients With Early-Stage Schizophrenia and Healthy Controls

  2022cites this paper
• Inflammation as a Pathophysiologic Pathway to Anhedonia: Mechanisms and Therapeutic Implications.

  2022cites this paper
• Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia

  2021cites this paper
• Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions

  2021cites this paper
• Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level

  2021cites this paper
• Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia

  2021cites this paper
• Cognitive control network connectivity differentially disrupted in treatment resistant schizophrenia

  2021cites this paper
• Neuroimaging Biomarkers in Schizophrenia.

  2021cites this paper
• Structural Covariance of Cortical Gyrification at Illness Onset in Treatment Resistance: A Longitudinal Study of First-Episode Psychoses

  2021influential citation
• Forecasting prognostic trajectories with mismatch negativity in early psychosis

  2021cites this paper
• Determinants of Schizophrenia Endophenotypes Based on Neuroimaging and Biochemical Parameters

  2021cites this paper
• Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia

  2021cites this paper
• Neurological Disorders: Biochemistry of Drug Resistance and Future Challenges

  2021cites this paper